These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 22237988)

  • 1. Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma.
    Rizk NP; Servais EL; Tang LH; Sima CS; Gerdes H; Fleisher M; Rusch VW; Adusumilli PS
    Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):482-6. PubMed ID: 22237988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
    Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
    Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma.
    Samuels TL; Altman KW; Gould JC; Kindel T; Bosler M; MacKinnon A; Hagen CE; Johnston N
    Laryngoscope; 2019 Dec; 129(12):2687-2695. PubMed ID: 31046139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SOX2 as a novel marker to predict neoplastic progression in Barrett's esophagus.
    van Olphen S; Biermann K; Spaander MC; Kastelein F; Steyerberg EW; Stoop HA; Bruno MJ; Looijenga LH
    Am J Gastroenterol; 2015 Oct; 110(10):1420-8. PubMed ID: 26323187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.
    Kauttu T; Mustonen H; Vainionpää S; Krogerus L; Ilonen I; Räsänen J; Salo J; Puolakkainen P
    Clin Transl Oncol; 2017 Jan; 19(1):58-66. PubMed ID: 27026568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms of Genes Related to Function and Metabolism of Vitamin D in Esophageal Adenocarcinoma.
    Singhal S; Kapoor H; Subramanian S; Agrawal DK; Mittal SK
    J Gastrointest Cancer; 2019 Dec; 50(4):867-878. PubMed ID: 30187205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acidic fibroblast growth factor is expressed sequentially in the progression from Barrett's esophagus to esophageal adenocarcinoma.
    Soslow RA; Petersen CG; Remotti H; Altorki N
    Dis Esophagus; 2001; 14(1):23-7. PubMed ID: 11422301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
    Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
    Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Expression of Cathepsin E in Tissues but Not Blood of Patients with Barrett's Esophagus and Adenocarcinoma.
    Fisher OM; Levert-Mignon AJ; Lord SJ; Botelho NK; Freeman AK; Thomas ML; Falkenback D; Wettstein A; Whiteman DC; Bobryshev YV; Lord RV
    Ann Surg Oncol; 2015 Jul; 22(7):2431-8. PubMed ID: 25348778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic changes in microRNA expression profiles reflect progression of Barrett's esophagus to esophageal adenocarcinoma.
    Slaby O; Srovnal J; Radova L; Gregar J; Juracek J; Luzna P; Svoboda M; Hajduch M; Ehrmann J
    Carcinogenesis; 2015 May; 36(5):521-7. PubMed ID: 25784377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Serum Glycoprotein Biomarker Candidates for Detection of Esophageal Adenocarcinoma and Surveillance of Barrett's Esophagus.
    Shah AK; Hartel G; Brown I; Winterford C; Na R; Cao KL; Spicer BA; Dunstone MA; Phillips WA; Lord RV; Barbour AP; Watson DI; Joshi V; Whiteman DC; Hill MM
    Mol Cell Proteomics; 2018 Dec; 17(12):2324-2334. PubMed ID: 30097534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of acidic fibroblast growth factor in Barrett's esophagus and associated esophageal adenocarcinoma.
    Soslow RA; Ying L; Altorki NK
    J Thorac Cardiovasc Surg; 1997 Nov; 114(5):838-43. PubMed ID: 9375615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil-Lymphocyte Ratio as a Marker of Progression from Non-Dysplastic Barrett's Esophagus to Esophageal Adenocarcinoma: a Cross-Sectional Retrospective Study.
    Campos VJ; Mazzini GS; Juchem JF; Gurski RR
    J Gastrointest Surg; 2020 Jan; 24(1):8-18. PubMed ID: 31745889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus.
    Critchley-Thorne RJ; Duits LC; Prichard JW; Davison JM; Jobe BA; Campbell BB; Zhang Y; Repa KA; Reese LM; Li J; Diehl DL; Jhala NC; Ginsberg G; DeMarshall M; Foxwell T; Zaidi AH; Lansing Taylor D; Rustgi AK; Bergman JJ; Falk GW
    Cancer Epidemiol Biomarkers Prev; 2016 Jun; 25(6):958-68. PubMed ID: 27197290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of COX-2, Ki-67, and BCL-2 expression in normal esophageal mucosa, Barrett's esophagus, dysplasia, and adenocarcinoma with postablation mucosa and implications for ablative therapies.
    Lewis CJ; Thrumurthy SG; Pritchard S; Armstrong G; Attwood SE
    Surg Endosc; 2011 Aug; 25(8):2564-9. PubMed ID: 21359892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
    Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
    Chatelain D; Fléjou JF
    Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Independent Blinded Validation of a Tissue Systems Pathology Test to Predict Progression in Patients With Barrett's Esophagus.
    Davison JM; Goldblum J; Grewal US; McGrath K; Fasanella K; Deitrick C; DeWard AD; Bossart EA; Hayward SL; Zhang Y; Critchley-Thorne RJ; Thota PN
    Am J Gastroenterol; 2020 Jun; 115(6):843-852. PubMed ID: 32079863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.